Dar15, I suggest you read the outcome of the 2022 rosacea trial, which was also the last hurdle before acne phase 3 can start. Certainly further ahead than we were in 2020 as you assert. My guess is BOT might try to avoid significant dilution to advance further trials by waiting for the sweaty drug to get approval, perhaps even revenue. Further delay doesn’t worry me, I’ve been here long enough that I can wait because I can smell money and with less dilution the more for me.
Ann: Investor Presentation, page-23
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
34.5¢ |
Change
-0.020(5.48%) |
Mkt cap ! $543.4M | |||
| Open | High | Low | Value | Volume |
| 35.5¢ | 35.5¢ | 34.0¢ | $4.566M | 13.13M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 410003 | 34.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 35.0¢ | 346713 | 8 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| BOT (ASX) Chart |